POSTMARKETING STUDY OF CARDIOVASCULAR ADVERSE REACTIONS ASSOCIATED WITH SUMATRIPTAN

被引:20
作者
OTTERVANGER, JP
VANWITSEN, TB
VALKENBURG, HA
STRICKER, BHC
机构
[1] NETHERLANDS CTR MONITORING ADVERSE DRUG REACT,POB 5406,2280 HK RIJSWIJK,NETHERLANDS
[2] UNIV GRONINGEN,CTR PHARM,SOCIAL PHARM SECT,GRONINGEN,NETHERLANDS
[3] ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS
基金
英国医学研究理事会;
关键词
D O I
10.1136/bmj.307.6913.1185
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
[No abstract available]
引用
收藏
页码:1185 / 1185
页数:1
相关论文
共 5 条
[1]   THE SAFETY AND TOLERABILITY OF SUMATRIPTAN - AN OVERVIEW [J].
BROWN, EG ;
ENDERSBY, CA ;
SMITH, RN ;
TALBOT, JCC .
EUROPEAN NEUROLOGY, 1991, 31 (05) :339-344
[2]   EFFECT OF SUBCUTANEOUS SUMATRIPTAN, A SELECTIVE 5HT1 AGONIST, ON THE SYSTEMIC, PULMONARY, AND CORONARY CIRCULATION [J].
MACINTYRE, PD ;
BHARGAVA, B ;
HOGG, KJ ;
GEMMILL, JD ;
HILLIS, WS .
CIRCULATION, 1993, 87 (02) :401-405
[3]   TRANSMURAL MYOCARDIAL-INFARCTION WITH SUMATRIPTAN [J].
OTTERVANGER, JP ;
PAALMAN, HJA ;
BOXMA, GL ;
STRICKER, BHC .
LANCET, 1993, 341 (8849) :861-862
[4]  
STRICKER BHC, 1992, BRIT MED J, V305, P118, DOI 10.1136/bmj.305.6845.118-a
[5]   CORONARY VASOSPASM INDUCED BY SUBCUTANEOUS SUMATRIPTAN [J].
WILLETT, F ;
CURZEN, N ;
ADAMS, J ;
ARMITAGE, M .
BRITISH MEDICAL JOURNAL, 1992, 304 (6839) :1415-1415